Gong P, Zhang Y, Song ZJ. Protective effects of edaravone on rats with severe acute pancreatitis.
Shijie Huaren Xiaohua Zazhi 2009;
17:31-35. [DOI:
10.11569/wcjd.v17.i1.31]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate the therapeutic effects and mechanism of edaravone on rats with severe acute pancreatitis (SAP) induced by L-arginine.
METHODS: A total of 60 rats were randomly and equally divided into three groups, namely control group, SAP model group and edaravone treatment group (n = 20). A SAP model was established by injecting intraperitoneally with L-arginine at a dose of 2.5 g/kg twice at an interval of 1 h, and injecting intravenously with edaravone 3 mg/kg, bid × 3 d (edaravone treatment group). The characteristics and volume of ascites, the pathological changes of pancreatic tissue and the serum levels of amylase (AMY), tumor necrosis factor-α (TNF-α), interleukin (IL)-6 and the contents of malonaldehyde (MDA), superoxide dismutase (SOD), glutathione (GSH) in pancreatic tissue of rats and prognosis were compared after 72 h following administration of L-arginine.
RESULTS: Compared with control group, 72 h after administration of L-arginine, SAP model group showed typical histopathological changes of SAP, elevated the volume of ascites (5.16 ± 1.52 vs 0.50 ± 0.10, P < 0.01), and significantly higher serum levels of AMY, TNF-α, IL-6 and content of MDA of pancreatic tissue (8967.5 ± 298.4 vs 720.1 ± 119.7I; 103.98 ± 10.56 vs 41.59 ± 3.79; 548.57 ± 10.45 vs 198.34 ± 2.10; 35.6 ± 3.8 vs 7.9 ± 2.2, all P < 0.01), and lower GSH and SOD in pancreatic tissue (7.2 ± 0.6 vs 17.1 ± 2.1; 7300 ± 1800 vs 28 400 ± 2700, both P < 0.01). Compared with SAP model group, 72 h after administration of L-arginine, significantly alleviated pathological lesions of SAP, decreased volume of ascites (4.05 ± 1.22 vs 53.16 ± 1.52, P < 0.05), lower pathological scores (P < 0.05), lower serum levels of AMY, TNF-α, IL-6 and MDA in pancreatic tissue (7809.5 ± 158.3 vs 8967.5 ± 298.4; 79.80 ± 14.23 vs 103.98 ± 10.56; 467 ± 6.64 vs548.57 ± 10.45; 29.1 ± 2.6 vs 35.6 ± 3.8, all P < 0.05), and higher GSH and SOD in pancreatic tissue were observed in edaravone treatment group (8.7 ± 1.3 vs 7.2 ± 0.6; 114 000 ± 27 000 vs 7300 ± 1800, both P < 0.05).
CONCLUSION: Edaravone can scavenge oxygen-derived free radicals, upgrade the contents of SOD and GSH in pancreatic tissue, decrease the serum levels of proinflammatory cytokines and, ameliorate the pathological lesions of pancreatic tissue in rats, and has a possibility of decreasing death rate.
Collapse